Rodriguez Belén, Schefold Joerg C, Z'Graggen Werner J
Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Clin Neurophysiol Pract. 2024 Aug 14;9:236-241. doi: 10.1016/j.cnp.2024.08.002. eCollection 2024.
Intensive care unit acquired weakness (ICUAW) is a clinical diagnosis and an umbrella term for acquired weakness due to neuromuscular disorders such as critical illness myopathy (CIM) but also muscular inactivity/atrophy. Without a clear understanding of the distinct aetiology, it seems difficult to predict outcomes of ICUAW and to test and apply effective future treatments. The present study contrasts ICUAW with CIM and assesses the diagnostic and clinical relevance for affected patients.
Data from a previous prospective cohort study investigating critically ill COVID-19 patients was analysed in a retrospective fashion. Patients were examined ten days after intubation with clinical assessment, nerve conduction studies, electromyography and muscle biopsy. Mortality was assessed during critical illness and at three months after hospital discharge. ICUAW and CIM were diagnosed according to the current diagnostic guidelines.
In this patient sample (n = 22), 92 % developed ICUAW, 55 % developed ICUAW and CIM, and 36 % had ICUAW but did not develop CIM. Overall, 27 % patients died during their stay in the intensive care unit. At three months after discharge, there were no further deaths, but in 14 % of patients the outcome was unknown. The diagnosis of CIM was more strongly associated with death during critical illness than ICUAW. No patient with ICUAW who did not fulfil the criteria for CIM died. Both clinical and electrophysiological criteria showed excellent sensitivity for CIM diagnosis, but only electrophysiological criteria had a high specificity. Determination of the myosin:actin ratio showed neither high sensitivity nor specificity for the diagnosis of CIM.
The results of the present study support that ICUAW is a non-specific clinical diagnosis of low predictive power with regard to mortality. Further, diagnosing "ICUAW" seems also of little research value for both exploring the aetiology and pathophysiology of muscle weakness in critically ill patients and for evaluating potential treatment effects. Thus, more specific diagnoses such as CIM are more appropriate. Within the different diagnostic criteria for CIM, electrophysiological studies are the most sensitive and specific examinations compared to clinical and muscle tissue assessment.
Avoiding an overarching diagnosis of "ICUAW" and instead focusing on specific diagnoses appears to have several relevant consequences: more precise diagnosis making, more accurate referral to aetiology and pathophysiology, improved outcome prediction, and development of more appropriate treatments.
重症监护病房获得性肌无力(ICUAW)是一种临床诊断,是因神经肌肉疾病(如危重病性肌病,CIM)以及肌肉失用/萎缩导致的获得性肌无力的统称。由于对其不同病因缺乏清晰认识,似乎难以预测ICUAW的预后,也难以测试和应用有效的未来治疗方法。本研究对ICUAW和CIM进行对比,并评估其对受影响患者的诊断及临床相关性。
对之前一项调查危重症COVID-19患者的前瞻性队列研究数据进行回顾性分析。患者在插管十天后接受临床评估、神经传导研究、肌电图检查和肌肉活检。评估危重症期间及出院后三个月的死亡率。根据当前诊断指南诊断ICUAW和CIM。
在这个患者样本(n = 22)中,92%发生了ICUAW,55%发生了ICUAW和CIM,36%发生了ICUAW但未发生CIM。总体而言,27%的患者在重症监护病房住院期间死亡。出院后三个月,无进一步死亡病例,但14%患者的结局未知。CIM的诊断与危重症期间的死亡关联比ICUAW更强。未符合CIM标准的ICUAW患者均未死亡。临床和电生理标准对CIM诊断均显示出极佳的敏感性,但只有电生理标准具有高特异性。肌球蛋白:肌动蛋白比值的测定对CIM诊断既无高敏感性也无高特异性。
本研究结果支持,ICUAW是一种对死亡率预测能力较低的非特异性临床诊断。此外,诊断“ICUAW”对于探究危重症患者肌肉无力的病因和病理生理学以及评估潜在治疗效果似乎也几乎没有研究价值。因此,更具体的诊断如CIM更为合适。在CIM的不同诊断标准中,与临床和肌肉组织评估相比,电生理研究是最敏感和特异的检查。
避免对“ICUAW”进行笼统诊断,转而关注具体诊断似乎会产生几个相关结果:更精确的诊断、更准确地追溯病因和病理生理学、改善预后预测以及开发更合适的治疗方法。